Page last updated: 2024-10-18

dalteparin and Shock

dalteparin has been researched along with Shock in 10 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Shock: A pathological condition manifested by failure to perfuse or oxygenate vital organs.

Research Excerpts

Excerpt	Relevance	Reference
"When a hematoma is large, the initial clinical picture may include hypovolemic shock, which may develop during surgery if the hematoma is not diagnosed early."	1.33	[Hypovolemic shock during surgery caused by a rectus sheath hematoma]. ( García, R; López-Escobar, M; Medina, C; Torres, LM; Vidal, MA, 2005)
"epigastrica superficialis."	1.32	[Serious complication after subcutaneous injection of heparin for prophylaxis of thromboembolism. Case report]. ( Andereya, S; Buschmeier, M; Hopf, KF; Kälicke, T; Muhr, G, 2003)

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (20.00)	18.2507
2000's	6 (60.00)	29.6817
2010's	2 (20.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Vidal, MA	1
López-Escobar, M	1
Medina, C	1
García, R	1
Torres, LM	1
Schneiter, S	1
Huynh-Do, U	1
Heizmann, M	1
Barkagan, ZS	1
Tsyvkina, LP	1
Koltakova, SI	1
Cyrkowicz, A	1
Rytwińska, E	1
Nytko, J	1
Słowińska-Zabówka, M	1
Shavadia, J	1
Welsh, R	1
Gershlick, A	1
Zheng, Y	1
Huber, K	1
Halvorsen, S	1
Steg, PG	1
Van de Werf, F	1
Armstrong, PW	1
Mizuno, S	1
Imai, H	1
Takaki, H	1
Tanemura, A	1
Kuriyama, N	1
Sakurai, H	1
Yamakado, K	1
Sakuma, H	1
Isaji, S	1
Andereya, S	1
Kälicke, T	1
Hopf, KF	1
Buschmeier, M	1
Muhr, G	1
Schneider, F	1
Assemi, P	1
Ba Faye, A	1
Sauer, B	1
Lutun, P	1
Haut, ER	1
Kamal, MK	1
Reilly, PM	1
Stavropoulos, SW	1
Burg, MD	1
Dallara, JJ	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623]			Phase 3	1,899 participants (Actual)	Interventional	2008-03-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Patients With All Cause Death and Non-fatal Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	50
Primary PCI (Group B)	43

Number of Patients With All Cause Death and Shock

This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	59
Primary PCI (Group B)	73

Number of Patients With All Cause Death and Shock and CHF

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	100
Primary PCI (Group B)	123

Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	117
Primary PCI (Group B)	135

Number of Patients With All Cause Death and Shock and Reinfarction

This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	77
Primary PCI (Group B)	85

Number of Patients With All Cause Mortality

This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	43
Primary PCI (Group B)	42

Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	116
Primary PCI (Group B)	135

Number of Patients With Cardiac Mortality

This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	31
Primary PCI (Group B)	32

Number of Patients With Cardiogenic Shock

This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	41
Primary PCI (Group B)	56

Number of Patients With Congestive Heart Failure (CHF)

This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	57
Primary PCI (Group B)	72

Number of Patients With Intracranial Haemorrhage

This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	9
Primary PCI (Group B)	2

Number of Patients With Ischaemic Stroke

This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	6
Primary PCI (Group B)	3

Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions

This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	61
Primary PCI (Group B)	45

Number of Patients With Minor Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	206
Primary PCI (Group B)	191

Number of Patients With Recurrent Myocardial Infarction (Reinfarction)

This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	23
Primary PCI (Group B)	21

Number of Patients With Rehospitalisation for Cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	45
Primary PCI (Group B)	41

Number of Patients With Rehospitalisation for Non-cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	19
Primary PCI (Group B)	11

Number of Patients With Serious Repeat Target Vessel Revascularization

This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	1
Primary PCI (Group B)	2

Number of Patients With Serious Resuscitated Ventricular Fibrillation

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	32
Primary PCI (Group B)	38

Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	10
Primary PCI (Group B)	29

Number of Patients With Total Disabling Stroke

This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	2
Primary PCI (Group B)	0

Number of Patients With Total Fatal Stroke

This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	7
Primary PCI (Group B)	4

Number of Patients With Total Non-disabling Stroke

This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	8
Primary PCI (Group B)	1

Number of Patients With Total Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	267
Primary PCI (Group B)	236

Number of Patients With Total Stroke (All Types)

This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	15
Primary PCI (Group B)	5

Trials

1 trial available for dalteparin and Shock

Article	Year
[Preparation for delivery in patients with missed labor considering low-dose heparin and prostaglandins]. Przeglad lekarski, 1996, Volume: 53, Issue:3 Topics: Adult; Anticoagulants; Delivery, Obstetric; Dinoprostone; Female; Hemorrhage; Humans; Labor, Induced	1996

Other Studies

9 other studies available for dalteparin and Shock

Article	Year
[Hypovolemic shock during surgery caused by a rectus sheath hematoma]. Revista espanola de anestesiologia y reanimacion, 2005, Volume: 52, Issue:8 Topics: Adenoma; Anticoagulants; Atrial Fibrillation; Hematoma; Humans; Intraoperative Complications; Male;	2005
[Bleeding complication due to accumulation of low-molecular-weight heparin in a patient with renal insufficiency]. Praxis, 2007, May-02, Volume: 96, Issue:18 Topics: Acute Kidney Injury; Adolescent; Age Factors; Aged; Anticoagulants; Anuria; Child; Creatinine; Enoxa	2007
[The ability of low-molecular heparin (Fraxiparin) to overcome the action of exogenous coagulases--a fundamental difference from nonfractionated heparin]. Biulleten' eksperimental'noi biologii i meditsiny, 1993, Volume: 116, Issue:10 Topics: Agkistrodon; Animals; Blood Coagulation; Coagulase; Crotalid Venoms; Dose-Response Relationship, Dru	1993
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Journal of the American Heart Association, 2016, 06-13, Volume: 5, Issue:6 Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F	2016
Spontaneous Rupture of an Intrasplenic Aneurysm After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. The Journal of emergency medicine, 2015, Volume: 48, Issue:6 Topics: Anticoagulants; Enoxaparin; Humans; Male; Shock; Splenic Rupture	2015
[Serious complication after subcutaneous injection of heparin for prophylaxis of thromboembolism. Case report]. Der Unfallchirurg, 2003, Volume: 106, Issue:2 Topics: Aged; Anticoagulants; Bursitis; Drug Administration Schedule; Elbow Joint; Enoxaparin; Epigastric Ar	2003
[A puzzling circulatory failure after total hip replacement]. Annales francaises d'anesthesie et de reanimation, 2003, Volume: 22, Issue:9 Topics: Acute Disease; Adrenal Insufficiency; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Fe	2003
Successful percutaneous retrieval of a swan-ganz catheter entrapped in an inferior vena cava filter. The Journal of trauma, 2007, Volume: 62, Issue:6 Topics: Aged, 80 and over; Anticoagulants; Catheterization, Swan-Ganz; Catheters, Indwelling; Colonoscopy; D	2007
Rupture of a previously normal spleen in association with enoxaparin: An unusual cause of shock. The Journal of emergency medicine, 2001, Volume: 20, Issue:4 Topics: Anticoagulants; Diagnosis, Differential; Enoxaparin; Humans; Injections, Subcutaneous; Laparotomy; M	2001